SCHEMBL762329

SCHEMBL762329

Nc1ncnn2ccc(-c3ccc([N+](=O)[O-])c(Cl)c3)c12

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DHFR P00374 1/20 0.43
MAPK1 P28482 2/20 0.38
TSHR P16473 1/20 0.38
PIK3CD O00329 1/20 0.38
PDE7A Q13946 1/20 0.37
MEN1 O00255 3/20 0.34
KMT2A Q03164 3/20 0.34
CYP3A4 P08684 3/20 0.34
ALDH1A1 P00352 3/20 0.34
CYP1A2 P05177 2/20 0.34
CYP2C19 P33261 2/20 0.34
MAPT P10636 2/20 0.34
TP53 P04637 1/20 0.34
CYP2D6 P10635 1/20 0.34
CYP2C9 P11712 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
HIF1A Q16665 1/20 0.34
F2 P00734 2/20 0.33
PRSS1 P07477 2/20 0.33
PRSS2 P07478 2/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15221827 0.80 MEN1 (0.55) PIK3CDMEN1KMT2ACYP3A4ALDH1A1
SCHEMBL27974840 0.76 TP53 (0.36) DHFRMAPK1TSHRPDE7AMEN1
SCHEMBL744320 0.76 FGFR1 (0.42) DHFRMAPK1TSHRPDE7ACYP3A4
SCHEMBL13892299 0.73 FGFR1 (0.37) CYP3A4ALDH1A1CYP1A2CYP2C19MAPT
SCHEMBL744286 0.71 EGFR (0.42) CYP3A4ALDH1A1CYP1A2CYP2C19MAPT
SCHEMBL762162 0.71 FGFR1 (0.33) DHFRMAPK1TSHRPIK3CDCYP3A4
SCHEMBL764040 0.71 FGFR1 (0.39) CYP3A4ALDH1A1CYP1A2CYP2C19TP53
SCHEMBL12909127 0.71 PIK3CD (0.43) MAPK1PIK3CDACVRL1AURKBAURKA
SCHEMBL742979 0.69 LMNA (0.39) CYP3A4CYP1A2CYP2C19MAPTCYP2D6
SCHEMBL30942187 0.69 MAP4K4 (0.47) MAPK1PIK3CDAURKBAURKAIKBKB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8138336-B2 Pyrrolotriazine derivatives useful for treating cancer through inhibition of aurora kinase BAYER HEALTHCARE LLC (US) 2012-03-20 US disclosed